{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125329","form_type":"8-K","ticker":"GUTS","cik":"0001572616","company_name":"FRACTYL HEALTH, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.837304+00:00","generated_at":"2026-05-30T01:54:05.275505+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fractyl Health Q3 net loss $23.2M; cash $84.7M; Revita studies on track","bullets":["Net loss $23.2M vs $15.7M YoY; R&D expense $19.0M (up from $9.4M) on clinical progress.","Cash and equivalents $84.7M; expected to fund operations into Q4 2025.","REMAIN-1 mid-point analysis expected Q2 2025; REVEAL-1 open-label data start Q4 2024.","REVITALIZE-1 topline data expected mid-2025; RJVA-001 CTA submission by YE 2024.","Nominated RJVA-002, first smart GIP/GLP-1 pancreatic gene therapy candidate for obesity."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125329","json":"https://secwatch.observer/filing/0000950170-24-125329.json","markdown":"https://secwatch.observer/filing/0000950170-24-125329.md","text":"https://secwatch.observer/filing/0000950170-24-125329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1572616/000095017024125329/0000950170-24-125329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1572616/000095017024125329/guts-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:54:05.275505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}